Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03988647 · ClinicalTrials.gov registry record · Phase 2
Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma
A Phase 2 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03988647: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT03988647 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03988647, a Phase 2 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The primary objectives of this study are to assess 1) the safety and 2) efficacy of combining Anti-PD-1/PD-L1 blockade with palliative radiation therapy in patients with Stage IV Merkel Cell Carcinoma.
Interventions
- DRUG Pembrolizumab
- RADIATION Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-07-24 |
| Est. Completion | 2021-01-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03988647
The ClinicalTrials.gov registry entry for NCT03988647 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03988647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03988647 about?
NCT03988647 is a clinical study titled "Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma". The primary objectives of this study are to assess 1) the safety and 2) efficacy of combining Anti-PD-1/PD-L1 blockade with palliative radiation therapy in patients with Stage IV Merkel Cell Carcinoma.
What is the current status of trial NCT03988647?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2019-07-24. Estimated completion is 2021-01-20.
What interventions are being tested in trial NCT03988647?
The interventions under investigation include: Pembrolizumab (DRUG), Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT03988647?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.